Article Versions Notes

Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, et al. Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma. Vaccines. 2024; 12(11):1249. https://doi.org/10.3390/vaccines12111249

Shoumariyeh, Khalid, Benedikt Csernalabics, Elahe Salimi Alizei, Matthias Reinscheid, Sebastian Giese, Kevin Ciminski, Georg Kochs, Martin Schwemmle, Julia Lang-Meli, Michelle Maas, and et al. 2024. "Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma" Vaccines 12, no. 11: 1249. https://doi.org/10.3390/vaccines12111249

Shoumariyeh, K., Csernalabics, B., Salimi Alizei, E., Reinscheid, M., Giese, S., Ciminski, K., Kochs, G., Schwemmle, M., Lang-Meli, J., Maas, M., Roehlen, N., Karl, V., Graeser, A., Sogukpinar, O., von Metzler, I., Grathwohl, D., Rasche, L., Hebart, H., Kull, M., ... Luxenburger, H. (2024). Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma. Vaccines, 12(11), 1249. https://doi.org/10.3390/vaccines12111249